GSK Vaccine Portfolio Gets A Shot In The Arm From ID Biomedical Buy

GlaxoSmithKline's proposed acquisition of ID Biomedical, announced Sept. 7, will bolster the drug maker's growing vaccine portfolio with the addition of Fluviral and several pipeline products